These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 21306997)

  • 1. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
    Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
    Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
    Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
    Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
    Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
    Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
    Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
    Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
    Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
    PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
    Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
    Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
    Wang M; Kern AM; Hülskötter M; Greninger P; Singh A; Pan Y; Chowdhury D; Krause M; Baumann M; Benes CH; Efstathiou JA; Settleman J; Willers H
    Cancer Res; 2014 May; 74(10):2825-34. PubMed ID: 24648348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
    Zhang XC; Zhang J; Li M; Huang XS; Yang XN; Zhong WZ; Xie L; Zhang L; Zhou M; Gavine P; Su X; Zheng L; Zhu G; Zhan P; Ji Q; Wu YL
    J Transl Med; 2013 Jul; 11():168. PubMed ID: 23842453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
    Jiang Y; Yuan Q; Fang Q
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
    Lee WY; Chen PC; Wu WS; Wu HC; Lan CH; Huang YH; Cheng CH; Chen KC; Lin CW
    Int J Cancer; 2017 Nov; 141(9):1921-1931. PubMed ID: 28710768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetics and biology of KRAS in lung cancer.
    Westcott PM; To MD
    Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
    Luk PP; Galettis P; Links M
    Lung Cancer; 2011 Sep; 73(3):274-82. PubMed ID: 21277645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.